```html

Neovascular Age‑Related Macular Degeneration (nAMD)

Overview

Neovascular age‑related macular degeneration (nAMD), also called “wet” AMD, is a progressive eye disease that damages the macula—the central part of the retina responsible for sharp, straight‑ahead vision. It is characterized by the growth of abnormal, fragile blood vessels beneath the retina that leak fluid or bleed, leading to rapid central vision loss.

nAMD typically affects older adults:

• Prevalence rises sharply after age 60; about 2–3 % of people over 65 have nAMD, compared with <1 % in those under 60 (CDC, 2023).
• It is the leading cause of severe visual impairment in high‑income countries, accounting for roughly 90 % of AMD‑related blindness (WHO, 2022).
• Women are slightly more likely to develop nAMD, reflecting longer life expectancy.

Symptoms

Symptoms often appear suddenly or worsen over weeks. Early detection is critical because treatment can preserve vision.

• Blurred or distorted central vision – straight lines may appear wavy (metamorphopsia).
• Dark or empty spot in the center of the visual field – may make reading or recognizing faces difficult.
• Difficulty with low‑contrast tasks such as driving at night or seeing steps.
• Colour perception changes – colours may look faded or washed out.
• Rapid vision loss – unlike the slow progression of dry AMD, nAMD can cause a noticeable drop in vision over days to weeks.
• Visual “flashing” or “floaters” – caused by bleeding from the abnormal vessels.

Causes and Risk Factors

Underlying Pathophysiology

nAMD results from an imbalance between pro‑angiogenic (blood‑vessel‑forming) and anti‑angiogenic factors in the retina. The key molecule is vascular endothelial growth factor (VEGF). When VEGF is over‑expressed, new vessels grow from the choroid (the vascular layer behind the retina) into the sub‑retinal space. These vessels are leaky, leading to fluid accumulation, scar formation, and photoreceptor death.

Major Risk Factors

• Age – risk doubles every decade after 60.
• Genetics – variants in the CFH and ARMS2 genes increase susceptibility (NEI, 2022).
• Race/ethnicity – higher prevalence in Caucasians; lower in African‑American and Asian populations.
• Smoking – current smokers have up to a 3‑fold increased risk (Mayo Clinic, 2023).
• Obesity & metabolic syndrome – linked to chronic inflammation and higher VEGF levels.
• Hypertension and cardiovascular disease – affect choroidal blood flow.
• High‑dose antioxidant supplements (e.g., beta‑carotene in smokers) can paradoxically increase lung‑cancer risk and are not recommended for AMD prevention.
• Previous diagnosis of dry AMD – about 10‑15 % of eyes with dry AMD progress to the neovascular form.
• Excessive sunlight exposure without UV protection – may accelerate retinal damage.

Diagnosis

nAMD is diagnosed by a retinal specialist (ophthalmologist or optometrist) using a combination of history, visual‑function testing, and imaging.

Clinical Examination

• Visual acuity test – measures distance vision using a Snellen chart.
• Amsler grid – a simple home tool; distortion indicates macular involvement.
• Dilated fundus examination – the doctor looks for signs of fluid, hemorrhage, or new vessels.

Imaging Modalities

• Optical Coherence Tomography (OCT) – cross‑sectional retinal images that reveal fluid accumulation, retinal thickness, and scar tissue. OCT is the gold‑standard for monitoring treatment response.
• Fluorescein Angiography (FA) – dye injected intravenously highlights leaking vessels.
• Indocyanine Green Angiography (ICGA) – better visualizes choroidal vasculature, useful for polypoidal lesions.
• Fundus Autofluorescence (FAF) – assesses retinal pigment epithelium health.

Laboratory Work‑up

Routine blood work is not required for diagnosis, but systemic work‑up (blood pressure, lipid profile, HbA1c) may be ordered to address modifiable risk factors.

Treatment Options

While nAMD cannot be cured, modern therapies can stabilize or even improve vision in many patients. Treatment is individualized based on lesion type, size, and patient health.

Anti‑VEGF Intravitreal Injections

The cornerstone of nAMD care. Medications bind VEGF, halting abnormal vessel growth.

• Ranibizumab (Lucentis) – FDA‑approved for nAMD; typical regimen: monthly for 3 months, then as‑needed (PRN) or treat‑and‑extend.
• Aflibercept (Eylea) – higher binding affinity; dosing every 8 weeks after 3 monthly loading doses.
• Brodalumab (Beovu) – 12‑week interval after loading dose.
• Pegaptanib (Macugen) – older agent, less commonly used.

Clinical trials (e.g., CATT, VIEW) show that > 30 % of patients gain ≥ 15 letters in visual acuity after 1 year of anti‑VEGF therapy (NEI, 2021).

Photodynamic Therapy (PDT)

Uses verteporfin (Visudyne) activated by a laser to close abnormal vessels. Often combined with anti‑VEGF for certain lesion types (e.g., polypoidal choroidal vasculopathy).

Laser Photocoagulation

Direct laser burns to seal leaking vessels; now rarely used because it can cause scotomas and is less effective than anti‑VEGF.

Surgical Options

• Vitrectomy – removal of vitreous hemorrhage or sub‑retinal blood.
• Sub‑macular surgery – experimental; not routinely recommended.

Lifestyle & Adjunct Therapies

• AREDS2 nutritional supplement – high‑dose vitamin C, vitamin E, zinc, copper, lutein & zeaxanthin may slow progression of dry AMD, though benefit in established nAMD is modest.
• Smoking cessation – reduces further vascular damage.
• Blood pressure and lipid control – antihypertensives, statins as indicated.

Living with Neovascular Age‑Related Macular Degeneration

Adjusting daily life helps maintain independence and quality of life.

Vision‑Enhancing Strategies

• Use high‑contrast, large‑print materials; adjust computer settings (increase font size, use dark mode).
• Bright, non‑glare lighting for reading and tasks.
• Magnifying devices – handheld, stand‑alone, or electronic (e.g., iPhone’s built‑in magnifier).
• Low‑vision rehabilitation services (often covered by Medicare/Medicaid).

Safety Tips

• Keep pathways clear; use night‑lights.
• Mark step edges with tactile or high‑contrast tape.
• When driving, consider a bi‑optic vehicle or limit driving to familiar routes and daylight.

Emotional & Social Support

• Join AMD support groups (American Macular Degeneration Foundation, local vision‑loss societies).
• Counselling or therapy can address anxiety/depression common with vision loss.

Adherence to Follow‑up

Anti‑VEGF injections often require visits every 4–12 weeks. Missing appointments can lead to irreversible vision loss. Set reminders, arrange transportation, and discuss any injection‑related concerns with your retina specialist.

Prevention

While age cannot be altered, several modifiable factors can lower the risk of developing nAMD or its progression.

• Quit smoking – seek nicotine‑replacement or counseling programs.
• Maintain a healthy weight – aim for BMI < 25 kg/m².
• Control blood pressure and cholesterol – regular check‑ups and adherence to prescribed meds.
• Protect eyes from UV & blue light – wear sunglasses with 99‑% UV‑A/B protection; consider lenses with blue‑light filtering for prolonged screen use.
• Adopt a diet rich in leafy greens, fish, and nuts – sources of lutein, zeaxanthin, omega‑3 fatty acids, which have been associated with lower AMD risk (Harvard Health, 2023).
• Regular eye examinations – at least annually after age 60, or more often if you have early AMD changes.

Complications

If left untreated, nAMD can lead to serious, often irreversible outcomes:

• Permanent central scotoma – a blind spot that interferes with reading and facial recognition.
• Scar tissue (fibrosis) – replaces healthy photoreceptors, cementing vision loss.
• Sub‑retinal hemorrhage – large bleeds can cause rapid, profound vision loss.
• Secondary cataract formation – intra‑ocular injections slightly increase cataract risk.
• Psychosocial impact – depression, loss of independence, increased fall risk.

When to Seek Emergency Care

---

© 2026 VisionHealth.com – All information provided is for educational purposes only and does not replace professional medical advice. Consult an eye‑care professional for personalized evaluation and treatment.

References

1. Centers for Disease Control and Prevention. Age‑Related Macular Degeneration (AMD) – Factsheet. 2023.
2. World Health Organization. Blindness and Vision Impairment. Global report, 2022.
3. Mayo Clinic. Neovascular (wet) macular degeneration. Updated 2023.
4. National Eye Institute (NEI). Age‑Related Macular Degeneration Clinical Trials (CATT, VIEW). 2021‑2022.
5. American Academy of Ophthalmology. Preferred Practice Pattern: Age‑Related Macular Degeneration. 2023.
6. Harvard Health Publishing. Diet and macular degeneration. 2023.

```